Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease cystic fibrosis
Symptom C2350529|pulmonary aspergillosis
Sentences 21
PubMedID- 20127304 Typical acute complications are infective exacerbations - the most frequent cause of death in cystic fibrosis - along with allergic bronchopulmonary aspergillosis, haemoptyses and pneumothoraces.
PubMedID- 24043500 Therefore, anti-ige therapy, using agents like omalizumab, may be a potential therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
PubMedID- 22608296 Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens.
PubMedID- 20714107 Vitamin d3 attenuates th2 responses to aspergillus fumigatus mounted by cd4+ t cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis.
PubMedID- 20597074 Risk factors for aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis.
PubMedID- 24167019 Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence.
PubMedID- 24248318 Early diagnosis and treatment of invasive pulmonary aspergillosis in a patient with cystic fibrosis.
PubMedID- 23278646 Hla-drb1 and hla-dqb1 genes on susceptibility to and protection from allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
PubMedID- 22696329 Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
PubMedID- 25010610 Anti ige antibody as treatment of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis.
PubMedID- 26003072 The classic diagnostic criteria of allergic bronchopulmonary aspergillosis in cystic fibrosis have been established during the cystic fibrosis foundation conference in 2001.
PubMedID- 25015245 Role of omalizumab in the management of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
PubMedID- 22731696 It is conceivable that high il-10 levels could contribute to the resolution of the aspergillus induced pulmonary inflammation, but high il-10 concentrations have also been associated with development of invasive aspergillosis in non-neutropenic immunocompromised patients and with colonization with a. fumigatus and allergic bronchopulmonary aspergillosis in patients with cystic fibrosis .
PubMedID- 25354514 Allergic bronchopulmonary aspergillosis affects patients with asthma and cystic fibrosis, and is important to recognise as permanent lung or airways damage may accrue if untreated.
PubMedID- 23278535 Immune response, diagnosis and treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis lung disease.
PubMedID- 22448043 Airway colonization with aspergillus causes allergic bronchopulmonary aspergillosis (abpa) in patients with cystic fibrosis or chronic asthma.
PubMedID- 25431975 Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
PubMedID- 26187954 Allergic bronchopulmonary aspergillosis affects patients with asthma and cystic fibrosis, and is important to recognise as permanent lung or airways damage may accrue if untreated.
PubMedID- 21067334 Serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis: state of the art and further challenges.
PubMedID- 25705310 Allergic bronchopulmonary aspergillosis in patient with cystic fibrosis - a case report.
PubMedID- 25150265 Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Page: 1